🔥 Tuesday 29 July 2025 Tue, 29 July 2025

Artemis Resources has secured $4.75 million in funding to launch a major drilling campaign across its gold, copper, and lithium projects in Western Australia, setting the stage for significant resource growth and development.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Resolution Minerals Limited is set to pursue a dual-listing on the NASDAQ in Q4 2025, aiming to tap into deeper U.S. capital markets and enhance its profile among American investors. The move supports the development of its critical minerals Horse Heaven project in Idaho, aligning with U.S. national security interests.

Liontown Resources reported robust FY25 results with over 294,000 dmt of spodumene concentrate produced and commenced underground mining on schedule. The company is transitioning to 100% underground production by Q3 FY26, aiming for scalable, low-cost operations from FY27 despite a 36% drop in spodumene prices.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Spenda Limited has reported a record-breaking FY25 with cash receipts soaring 114% to $11.5 million and launched its APG Pay platform backed by a $50 million funding commitment. The company also trimmed operating costs by 39%, setting a leaner foundation for FY26 growth.

Australian Rare Earths Limited (ASX, AR3) reports successful metallurgical testwork at its Koppamurra Rare Earths Project, producing 34kg of Mixed Rare Earth Oxide from heap leach solutions, paving the way for streamlined, cost-effective rare earth processing.

Anson Resources has announced a maiden JORC lithium resource of 103,000 tonnes LCE at its Green River Project in Utah, with plans to expand through historic well re-entry and a new collaboration with POSCO for lithium extraction technology.

Yojee Limited has unveiled its next-generation MOSAIC platform prototype to strong industry acclaim, completed critical technical validation for its SmartYojee customs technology, and secured a $5.4 million capital raise to fuel growth and commercialisation.

Petratherm Limited has significantly expanded its Rosewood Titanium Discovery at the Muckanippie Project through Phase 2 drilling, revealing high-grade mineralisation over a 20km² area that remains open to the north. The company also completed Phase 3 drilling and strengthened its leadership with a key executive appointment.

Liontown Resources capped its first year at Kathleen Valley with over 300,000 tonnes of spodumene concentrate produced and a record $23 million in operating cash flow, despite a challenging lithium price environment. The company is on track to complete open pit mining by year-end and fully transition to underground operations by Q3 FY26.

Leeuwin Metals has reported strong high-grade gold assay results from its latest drilling at the Marda Gold Project, with significant mineralisation extending below existing pits and new targets identified. The company aims to deliver a maiden Mineral Resource Estimate this quarter, supported by ongoing exploration and drilling.

VHM Limited has secured a crucial mining licence for its Goschen Rare Earths and Mineral Sands Project, alongside key domestic and international partnerships and a successful $8.6 million capital raise.

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

Alpha HPA Limited has kicked off major civil works for its HPA First Project Stage 2 while securing strong sales momentum in the semiconductor sector, supported by expanded Letters of Intent covering over 60% of Stage 2 capacity.

PhosCo Ltd has unveiled a significant phosphate discovery at its KM Prospect in Tunisia, featuring thick, shallow mineralisation close to the planned processing plant. This breakthrough could fast-track development and improve project economics at the Gasaat Project.

Kalamazoo Resources retains 100% ownership of its 1.44 million ounce Ashburton Gold Project and fast-tracks a scoping study amid soaring Australian gold prices. The company aims to unlock significant value from the Mt Olympus Deposit with a targeted study completion in Q4 2025.

Beacon Minerals has completed an 8-hole diamond drilling program at its Iguana deposit, revealing significant high-grade gold mineralisation and confirming geotechnical stability for pit designs. These findings set the stage for an updated resource model and future development plans.

Firetail Resources has revealed a significant expansion of gold discovery potential at its Excelsior Gold Project in Nevada, identifying a 5km strike extension of the Buster Trend and confirming a parallel Ghost Trend. The company is poised to begin diamond drilling in August to test these promising targets.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Acrow Limited confirms FY25 financial guidance with solid sales and EBITDA growth, while securing a significant seven-year contract extension with Origin Energy that bolsters its Industrial Access division outlook for FY26.

Bastion Mining has taken control of over 90% of Xanadu Mines shares through a takeover bid, moving swiftly to compulsory acquisition and setting the stage for the Kharmagtai project’s next phase.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.